IQVIA Holdings Inc. $IQV Shares Purchased by Clearstead Trust LLC

Clearstead Trust LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2,677.2% in the 4th quarter, HoldingsChannel reports. The firm owned 4,138 shares of the medical research company’s stock after purchasing an additional 3,989 shares during the period. Clearstead Trust LLC’s holdings in IQVIA were worth $933,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Eubel Brady & Suttman Asset Management Inc. acquired a new position in shares of IQVIA during the 3rd quarter worth about $14,278,000. Eagle Rock Investment Company LLC boosted its position in shares of IQVIA by 33.6% during the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after acquiring an additional 11,657 shares in the last quarter. OPTIMAS CAPITAL Ltd acquired a new position in shares of IQVIA during the 3rd quarter worth about $4,008,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new position in shares of IQVIA during the 3rd quarter worth about $7,368,000. Finally, AMG National Trust Bank acquired a new position in shares of IQVIA during the 3rd quarter worth about $3,713,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Up 0.2%

Shares of NYSE IQV opened at $168.28 on Monday. The stock has a market cap of $28.09 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The business has a 50-day moving average price of $169.72 and a 200 day moving average price of $197.45.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on IQV shares. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. UBS Group lowered their price objective on IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Royal Bank Of Canada started coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. BMO Capital Markets set a $250.00 price objective on IQVIA in a research report on Friday, February 6th. Finally, TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and upped their price objective for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.